BIRC5 and chronic myelogenous leukemia, BCR-ABL1 positive: Overall, this study indicates the role of the HALOA complex as a new therapeutic target for drug-resistant chronic myeloid leukemia (CML) by enhancing total antioxidant activity and triggering apoptosis at the G2/M phase of cell cycle via lowering the expression level of survivin.